From: Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
Antigen | Product name* (NCT) | Study sponsor | Estimated enrollment | Country | Clinical Update reference |
---|---|---|---|---|---|
CAR-T cells | Â | Â | Â | Â | Â |
BCMA | JNJ-68284528 (NCT03548207) | Janssen | 118 | United States, Japan | 2020 ASH [7] |
BCMA | bb21217 (NCT03274219) | Bluebird | 74 | United States | 2020 ASH [8] |
NY-ESO-1 | GSK3377794 (NCT03168438) | GlaxoSmithKline | 20 | United States | 2019 ASH [9] |
BCMA /CD19 | GC012F (NCT04236011) | Shanghai Changzheng Hospital | 15 | China | 2020 ASH [10] |
BCMA/CD38 | BM 38CAR (ChiCTR1800018143) | Wuhan Tongji Medical College Union Hospital | 20 | China | 2019 ASH [11] |
BCMA | ALLO-715 (NCT04093596) | Allogene | 90 | United States | 2020 ASH [12] |
Bispecific antibody (BiTE) | Â | Â | Â | Â | Â |
BCMA × CD3 | Teclistamab JNJ-64007957 (NCT03145181) | Janssen | 160 | United States, the Netherlands, Spain, Sweden | 2020 ASH [13] |
BCMA × CD3 | CC-93269 (NCT03486067) | Celgene | 115 | United States, Spain | 2019 ASH [14] |
BCMA × CD3 | PF-06863135 (NCT03269136) | Pfizer | 80 | United States, Canada | 2020 ASH [15] |
BCMA × CD3 | TNB-383B (NCT03933735) | Tenebio AbbVie | 72 | United States | 2020 ASH [16] |
BCMA × CD3 | REGN5458 (NCT03761108) | Regeneron | 74 | United States, Belgium | 2020 ASH [17] |
GPRC5D × CD3 | Talquetamab JNJ-64407564 (NCT03399799) | Janssen | 245 | United States, Netherlands, Spain | 2020 ASH [18] |
FcRH5 × CD3 | BFCR4350A (NCT03275103) | Genentech | 300 | United States, Australia, Canada, Spain | 2020 ASH [19] |
Antibody–drug conjugate (ADC) |  |  |  |  |  |
BCMA, pyrrolobenzodiazepine | MEDI2228 (NCT03489525) | MedImmune | 142 | United States, Australia, Greece | 2020 ASH [20] |
BCMA, Shiga-like toxin-A subunit (engineered toxin bodies) | TAK-169 (NCT04017130) | Millennium Takeda | 102 | United States | 2019 ASH [21] |
Monoclonal antibody (MoAb) | Â | Â | Â | Â | Â |
CD38 | TAK-079 (NCT03439280) | Millennium Takeda | 100 | United States | 2020 ASCO [22] |
CD38 with interferon | TAK-573 (NCT03215030) | Millennium Takeda | 151 | United States | 2020 ASH [23] |
CD38 | SAR442085 (NCT04000282) | Sanofi | 78 | United States, France, Spain | 2020 AACR[24] |
Small molecule inhibitors and modulators | Â | Â | Â | Â | Â |
BCL-2 inhibitor | Venetoclax (NCT03314181, NCT01794520) | AbbVie | 104, 117 | United States, Australia, Belgium, Canada, Denmark, France, Germany, Norway | |
BCL-2 inhibitor | AT-101 (NCT02697344) | Mayo Clinic | 10 | United States | 2019 ASH [27] |
HDAC inhibitor | Alteminostat (NCT03150316) | Chong Kun Dang Pharamaceutical | 18 | South Korea | 2019 ASH [28] |
HDAC inhibitor | Chidamide (NCT04025450) | The First Affiliated Hospital of Soochow University | 50 (high-risk NDMM) | China | 2019 ASH [29] |
Cereblon E3 ligase modulator | Iberdomide (CC-220) (NCT02773030) | Celgene | 449 | United States, France, Germany, Italy, Japan, the Netherlands, Spain, United Kingdom | 2020 ASH [30] |
Cereblon E3 ligase modulator | CC-92480 (NCT03374085) | Celgene | 80 | United States, Canada, Denmark, Finland, Spain, United Kingdom | 2020 ASH [31] |
MEK inhibitor | Cobimetinib (NCT03312530) | Hoffmann-La Roche | 72 | Czechia, Denmark, France, Germany, Netherlands, Norway, Poland, Spain, Sweden | 2020 ASH [32] |
MEK and BRAF inhibitors | Encorafenib and binimetinib (NCT02834364) | University of Heidelberg | 12 | Germany | 2020 ASH [33] |
Other therapies | Â | Â | Â | Â | Â |
Peptidase enhanced cytotoxic | Melflufen (NCT03481556) | Oncopeptides | 80 | United States, Czechia, Spain | 2020 ASH [34] |
Peptidase enhanced cytotoxic | Melflufen (NCT02963493) | Oncopeptides | 157 | United States, France, Italy, Spain | 2020 ASCO [35] |